Fexocon

• Approved Indications:
• Seasonal Allergic Rhinitis (SAR): For the relief of symptoms associated with seasonal allergic rhinitis, including sneezing, rhinorrhea, nasal itching, and itchy, watery or red eyes in adults and children, according to age and formulation specific approvals. [1, 2, 3, 4]
• Chronic Idiopathic Urticaria (CIU) / Chronic Spontaneous Urticaria (CSU): For the relief of symptoms of chronic idiopathic urticaria, including pruritus (itching) and urticaria (hives), in adults and children according to approved age and dosage form restrictions. [1, 2, 3, 4]
• Off-label / Clinically Accepted Uses:
• Chronic Urticaria Higher dose Therapy: In patients with inadequate symptom control on standard doses of second generation H1 antihistamines, international guidelines recommend increasing the dose up to four times the standard dose. Fexofenadine may be used in this approach under physician supervision. This is an off-label dosing strategy. [5]
• Important indication note: Approved indications vary by country, age group, and dosage form. For example, the UK 120 mg tablet is indicated for seasonal allergic rhinitis, whereas the 180 mg tablet is indicated for chronic idiopathic urticaria. [2, 3] The US prescribing information also includes pediatric chronic idiopathic urticaria for oral suspension. [1]

• Route: Oral.
• Adults:
• Rheumatoid arthritis: 200 mg once daily, with or without methotrexate.
• Ulcerative colitis: Induction dose typically 200 mg once daily for 10 weeks; maintenance dose 100 mg once daily.
• Crohn’s disease: Dose may vary, typically 200 mg once daily.
• Pediatrics:
• Safety and efficacy not established; use generally not recommended.
• Elderly:
• No specific dose adjustment necessary, but monitor for adverse effects.
• Renal impairment:
• Mild to moderate impairment: No dose adjustment required.
• Severe impairment or end-stage renal disease: Use with caution; limited data.
• Hepatic impairment:
• Mild to moderate impairment: No dose adjustment required.
• Severe impairment: Not recommended due to limited safety data.
• Administration Notes:
• Can be taken with or without food.
• Swallow whole with water.

Filgotinib maleate is a selective Janus kinase 1 (JAK1) inhibitor. By selectively inhibiting JAK1, filgotinib blocks the signaling pathways of pro-inflammatory cytokines that utilize the JAK-STAT pathway, such as interleukins and interferons. This results in downregulation of immune-mediated inflammatory responses, reducing inflammation, joint damage, and symptoms in autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease.

• Absorption: Rapid oral absorption; peak plasma concentrations reached within 2-3 hours.
• Bioavailability: Approximately 80%.
• Distribution: Volume of distribution ~ 300 L, moderate plasma protein binding (~55%).
• Metabolism: Primarily metabolized by carboxylesterases to an active metabolite with similar JAK1 selectivity.
• Active Metabolite: Exhibits similar pharmacological activity; prolongs therapeutic effect.
• Elimination: Excreted mainly via urine (≈85%), with minor fecal elimination.
• Half-life: Parent drug ~6 hours; active metabolite ~23 hours.
• Onset of action: Clinical effects observed within weeks of therapy initiation.

• Pregnancy: No well-controlled human studies available; animal studies have shown reproductive toxicity at high doses. Use only if benefits justify potential risks.
• Lactation: Unknown if excreted in human milk; breastfeeding is not recommended during treatment and for 4 weeks after discontinuation.

• Janus kinase (JAK) inhibitor.
• Targeted synthetic disease-modifying antirheumatic drug (tsDMARD).

• Known hypersensitivity to filgotinib or any excipients.
• Active serious infections (e.g., tuberculosis, sepsis).
• Severe hepatic impairment (due to lack of safety data).

• Increased risk of serious infections including tuberculosis, fungal infections, and viral infections.
• Monitor for signs of infection; discontinue if serious infection develops.
• Screen for latent tuberculosis prior to treatment initiation.
• Avoid use in patients with severe hepatic or renal impairment unless benefit outweighs risk.
• Monitor blood counts (CBC) regularly for cytopenias.
• Caution in patients at risk for thrombosis; JAK inhibitors have been associated with thromboembolic events.
• Risk of gastrointestinal perforation in patients with diverticulitis or on concomitant NSAIDs, corticosteroids.
• Avoid live vaccines during and shortly after treatment.
• Not recommended during pregnancy or breastfeeding unless clearly necessary.

• Common:
• Upper respiratory tract infections.
• Nausea.
• Headache.
• Elevated liver enzymes (mild).
• Increased creatinine kinase.
• Serious but less common:
• Serious infections.
• Herpes zoster reactivation.
• Thromboembolic events (deep vein thrombosis, pulmonary embolism).
• Cytopenias (anemia, neutropenia).
• Elevated lipid levels.
• Rare:
• Gastrointestinal perforation.
• Malignancies (rare reports with JAK inhibitors).

• Substrate of CYP3A4: strong CYP3A4 inducers (e.g., rifampicin) may reduce filgotinib levels; avoid or monitor therapy.
• No significant inhibition or induction of CYP450 enzymes by filgotinib.
• Concomitant immunosuppressants may increase infection risk.
• Avoid live vaccines during therapy.
• No significant interaction with food.

• FDA and EMA approvals expanding for use in moderate to severe ulcerative colitis.
• Updated safety warnings emphasize infection risk and thrombosis risk monitoring.
• Recent guidelines recommend pre-treatment screening for latent infections and regular blood monitoring during therapy.
• Dose adjustments being evaluated for special populations in ongoing studies.

• Store at controlled room temperature: 20°C to 25°C (68°F to 77°F).
• Protect from moisture and light.
• Keep tablets in original container tightly closed.
• Keep out of reach of children.